
HONG KONG, Sep 1, 2020 - (ACN Newswire) - Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) ("Aptorum Group"), a biopharmaceutical company focused on the development of novel therapeutics including orphan diseases and oncology indications, announced further positive data from its latest in vivo studies showing significant activity against...
Read more: Aptorum Group Announces Further Positive Data on SACT-1 Against Neuroblastoma and Other Potential...